The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: A meta-analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zang, Leyuan ^a   Ma, Min ^a   Hu, Jianxin ^a   Qiu, Hao ^a   Huang, Bo ^a   Chu, Tongwei ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN; TNFRSF11B PROTEIN, HUMAN;

BLOOD; BONE TUMOR; HUMAN; LUNG TUMOR; MALE; META ANALYSIS; METASTASIS; PATHOLOGY; PROSTATE TUMOR; SECONDARY;

BONE NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; OSTEOPROTEGERIN; PROSTATIC NEOPLASMS;

EID: 84950286527     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18324     Document Type: Article

References (53)

1. Riccio, A. I., Wodajo, F. M. & Malawer, M. Metastatic carcinoma of the long bones. Am. Fam. Physician 76, 1489-1494 (2007).
2. Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593 (2002).
3. Yin, J. J., Pollock, C. B. & Kelly, K. Mechanisms of cancer metastasis to the bone. Cell Res. 15, 57-62 (2005).
4. Keller, E. T. et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev. 20, 333-349 (2001).
5. Bubendorf, L. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31, 578-583 (2000).
6. Coleman, R. E. Skeletal complications of malignancy. Cancer 80, 1558-1594 (1997).
7. Furukawa, M., Ohta, T. & Xiong, Y. Activation of UBC5 ubiquitin-conjugating enzyme by the RING finger of ROC1 and assembly of active ubiquitin li-gases by all cullins. J. Biol. Chem. 277, 15758-15765 (2002).
8. Destombe, C. et al. Investigation for bone metastasis from an unknown primary. Joint Bone Spine 74, 85-89 (2007).
9. Voorzanger-Rousselot, N. et al. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br. J. Cancer 95, 506-514 (2006).
10. Zhao, H. et al. Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors. Med. Sci. Monit. 17, CR626-CR633 (2011).
11. Fontana, A. & Delmas, P. D. Markers of bone turnover in bone metastases. Cancer 88, 2952-2960 (2000).
12. Penno, H. et al. Osteoprotegerin secretion from prostate cancer isstimulated by cytokines, in vitro. Biochem. Biophys. Res. Commun. 293, 451-455 (2002).
13. Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
14. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of non-randomized studies in metaanalyses. Eur. J. Epidemiol. 25, 603-605 (2010).
15. Chen, H. X. et al. Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer. Chin. J. Surg. 45, 412-414 (2007).
16. Roato, I. et al. Osteoclasts are active in bone forming metastases of prostate cancer patients. Plos One 3, e3627 (2008).
17. Terpos, E. et al. The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res. 29, 1651-1658 (2009).
18. Yin, J. L. & Chen, X. Y. The clinical value of serum osteoprotegerin level in the diagnosis of lung cancer. Exp. Lab. Med. 27, 7-9 (2009).
19. Zhao, X. Z. et al. Clinical value of measuring serum osteoprotegerin in patients with prostate cancer. Clinical Medicine of China 26, 1242-1243 (2010).
20. Karapanagiotou, E. M. et al. Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med. Oncol. 27, 332-338 (2010).
21. Kamiya, N. et al. Significance of serum osteoprotegerin and receptor activator of nuclear factor B ligand in Japanese prostate cancer patients with bone metastasis. Int. J. Clin. Oncol. 16, 366-372 (2011).
22. Zhu, B., Shao, K. J., Yuan, H. & Xu, Y. F. The clinical assessment on lesions shown 99mTc-MDP whole body bone scan and determination of serum levels of OPG, BSP and TRACP-5b in lung cancerpatients with bone metastasis. J. Radioimmunology. 26, 545-547 (2013).
23. Bu, J. S. Changes and clinical significance of serum OPG, BMP-7 and PSA in patients with prostatic cancer. Chinese Journal of Health Laboratory Technology 23, 168-170 (2013).
24. Li, L., Tan, B. Y., Liu, Z. W., Chen, M. & Zhang, Y. The diagnostic value of serum osteoclast differentiation factor and inhibitory factor in bone metastasis of lung cancer. Int. J. Lab. Med. 34, 1930-1934 (2013).
25. Tan, Y. C. Significance of ODF and OCIF in diagnosis of prostate cancer bone metastases. China Journal of Modern Medicine 24, 37-40 (2014)
26. Schaller, B. et al. Prostate-specific antigen in the cerebrospinal fluid leads to diagnosis of solitary cauda equina metastasis: a unique case report and review of the literature. Br. J. Cancer 77, 2386-2389 (1998).
27. Paget, S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 8, 98-101 (1989).
28. Gregory, R. & Mundy, M. D. Mechanisms of bone metastasis. Cancer 80, 1546-1556 (1997).
29. Neville-Webbe, H. L. et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAILinduced apoptosis. Breast Cancer Res. Treat. 86, 269-279 (2004).
30. Hofbauer, L. C. & Schoppet, M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292, 490-495 (2004).
31. Nagai, M., Kyakumoto, S. & Sato, N. Cancer cells responsible for humoral hypercalcaemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem. Biophys. Res. Commun. 269, 532-536 (2000).
32. Huang, L., Cheng, Y. Y., Chow, L. T., Kumta, S. M. & Zheng, M. H. Tumor cells produce receptor activator of NF-kB ligand (RANKL) in skeletal metastases. J. Clin. Pathol. 55, 877-878 (2002).
33. Jung, K. et al. Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin. Chem. 47, 2061-2063 (2001).
34. Udawela, M., Hay, D. L. & Sexton, P. M. The receptor activity modifying protein family of G protein coupled receptor accessory proteins. Semin. Cell Dev. Biol. 15, 299-308 (2004).
35. Theoleyre, S. et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodelling. Cytokine Growth Factor Rev. 15, 457-475 (2004).
36. Holen, I. & Shipman, C. M. Role of osteoprotegerin (OPG) in cancer. Clin. Sci. 110, 279-291 (2006).
37. Grimaud, E. et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am. J. Pathol. 163, 2021-2031 (2003).
38. Terpos, E. et al. Soluble receptor activator of nuclear factor kappa-B ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102, 1064-1069 (2003).
39. Rosen, L. S. et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21, 3150-3157 (2003).
40. Russell, R. G., Watts, N. B., Ebetino, F. H. & Rogers, M. J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19, 733-759 (2008).
41. Rogers, M. J., Crockett, J. C., Coxon, F. P. & Mönkkönen, J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49, 34-41 (2010).
42. Sun, L. & Yu, S. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis. Am. J. Clin. Oncol. 36, 399-403 (2013).
43. Henry, D. et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer 22, 679-87 (2014).
44. Zhang, J. et al. Osteoprotegerin inhibits prostate cancer induced osteoclastogenesis and prevents tumor growth in the bone. J. Clin. Invest. 107, 1235-1244 (2001).
45. Miller, R. E. et al. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol. Cancer Ther. 7, 2160-2169 (2008).
46. Hakeda, Y. et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. Biochem. Biophys. Res. Commun. 251, 796-801 (1998).
47. Reddi, A. H., Roodman, D., Freeman, C. & Mohla, S. Mechanisms of tumor metastasis to the bone: challenges and opportunities. J. Bone Miner. Res. 18, 190-194 (2003).
48. Akatsu, T. et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem. Biophys. Res. Commun. 250, 229-234 (1998).
49. Holen, I., Crouche, P. I., Hamdy, F. C. & Eaton, C. L. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62, 1619-1623 (2002).
50. Nyambo, R. et al. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J. Bone Miner. Res. 191, 712-1721 (2004).
51. Park, H. R. et al. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. J. Korean Med. Sci. 18, 541-546 (2003).
52. Holen, I. et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo-a role in tumour cell survival Breast Cancer Res. Treat. 92, 207-215 (2005).
53. Cross, S. S. et al. Osteoprotegerin (OPG)-a potential new role inthe regulation of endothelial cell phenotype and tumour angiogenesis Int. J. Cancer 118, 1901-1908 (2006).